Scientific ReportsNeurosciencePeer-reviewed journal article
Motivational, proteostatic and transcriptional deficits precede synapse loss, gliosis and neurodegeneration in the B6.HttQ111/+ model of Huntington’s disease
Robert M. BraggiD, Sydney R. CoffeyiD, Rory M. WestoniD, Seth A. AmentiD, Jeffrey P. CantleiD, Shawn Minnig, Cory C. FunkiD, Dominic D. Shuttleworth, Emily L. Woods, Bonnie R. SullivaniD, Lindsey Jones, Anne Glickenhaus, John S. Anderson, Michael D. Anderson, Stephen B. DunnettiD, Vanessa Chantal WheeleriD, Marcy E. MacDonald, Simon P. BrooksiD, Nathan D. PriceiD, Jeffrey B. CarrolliD
Abstract
We investigated the appearance and progression of disease-relevant signs in the B6.HttQ111/+ mouse, a genetically precise model of the mutation that causes Huntingtons disease (HD). We find that B6.HttQ111/+ mice are healthy, show no overt signs of central or peripheral inflammation, and no gross motor impairment as late as 12 months of age. Behaviorally, we find that 4-9 month old B6.HttQ111/+ mice have normal activity levels and show no clear signs of anxiety or depression, but do show clear signs of reduced motivation. The neuronal density, neuronal size, synaptic density and number of glia is normal in B6.HttQ111/+ striatum, the most vulnerable brain region in HD, up to 12 months of age. Despite this preservation of the synaptic and cellular composition of the striatum, we observe clear progressive, striatal-specific, transcriptional dysregulation and accumulation of neuronal intranuclear inclusions (NIIs). Simulation studies suggest these molecular endpoints are sufficiently robust for future preclinical studies, and that B6.HttQ111/+ mice are a useful tool for modeling disease-modifying or neuroprotective strategies for disease processes before the onset of overt phenotypes.
- Citations
- 21
- FWCI
- 1.47
- Field percentile
- top 22%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Peripheral Htt silencing does not ameliorate central signs of disease in the B6. HttQ111/+ mouse model of Huntington’s Disease
Sydney R. Coffey, Robert M. Bragg, … Jeffrey B. Carroll·PLoS ONEPeer-reviewed·Apr 28, 2017
- Evidence for glutamate excitotoxicity that occurs before the onset of striatal cell loss and motor symptoms in an ovine Huntington's Disease model.
Andrew Jiang, Linya You, … Russell G. Snell·bioRxiv·Jun 20, 2023
- Benefits of global mutant huntingtin lowering diminish over time in a Huntington's disease mouse model
Deanna M. Marchionini, Jeh-Ping Liu, … Scott O. Zeitlin·JCI InsightPeer-reviewed·Oct 23, 2022
- Mapping brain volume changes in the zQ175DN mouse model of Huntington's disease: a longitudinal MRI study
Nicholas Vidas-Guscic, Tamara Vasilkovska, … Marleen Verhoye·Biomarker ResearchPeer-reviewed·Sep 1, 2026
- Modulating glial genes involved in synaptic function mitigates pathogenesis and behavioral deficits in a Drosophila model of Huntington's Disease
Tarik Seref Onur, Andrew Laitman, … Juan Botas·bioRxiv·Nov 3, 2020
- Enhanced Hippocampal Spare Capacity in Q175DN Mice Despite Elevated mHTT Aggregation
Melissa A Solem, Ross J. Pelzel, … Rocío Gómez‐Pastor·bioRxiv·Oct 14, 2024